Milotka Fabri

427 total citations
27 papers, 223 citations indexed

About

Milotka Fabri is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Milotka Fabri has authored 27 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hepatology, 17 papers in Epidemiology and 2 papers in Infectious Diseases. Recurrent topics in Milotka Fabri's work include Hepatitis C virus research (17 papers), Hepatitis B Virus Studies (14 papers) and Liver Disease Diagnosis and Treatment (11 papers). Milotka Fabri is often cited by papers focused on Hepatitis C virus research (17 papers), Hepatitis B Virus Studies (14 papers) and Liver Disease Diagnosis and Treatment (11 papers). Milotka Fabri collaborates with scholars based in Serbia, United States and New Zealand. Milotka Fabri's co-authors include Petr Husa, Edward Gane, Phillip Dinh, Andrzej Horban, Benedetta Massetto, Peter Kwan, Scott Fung, G. Mani Subramanian, John F. Flaherty and Mijomir Pelemiš and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Journal of Hepatology.

In The Last Decade

Milotka Fabri

26 papers receiving 216 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Milotka Fabri Serbia	6	165	163	48	15	13	27	223
Pasqualina De Leo Italy	8	150 0.9×	115 0.7×	29 0.6×	15 1.0×	21 1.6×	23	246
Paola Zuccalà Italy	8	125 0.8×	130 0.8×	77 1.6×	25 1.7×	5 0.4×	13	278
P Kokordelis Germany	8	119 0.7×	159 1.0×	35 0.7×	13 0.9×	3 0.2×	13	256
Ewa Majda-Stanisławska Poland	10	143 0.9×	59 0.4×	48 1.0×	18 1.2×	5 0.4×	30	232
Ossama Ashraf Ahmed Egypt	7	162 1.0×	180 1.1×	23 0.5×	9 0.6×	21 1.6×	27	226
Shahnaz Sali Iran	9	195 1.2×	156 1.0×	60 1.3×	8 0.5×	2 0.2×	44	287
Sonny Michael Assennato United Kingdom	6	126 0.8×	97 0.6×	59 1.2×	14 0.9×	10 0.8×	11	261
Tiziana Tieghi Italy	8	130 0.8×	139 0.9×	36 0.8×	22 1.5×	2 0.2×	14	248
Neddie Zadeikis United States	8	160 1.0×	144 0.9×	62 1.3×	5 0.3×	5 0.4×	10	203
Waleed K. Al‐Hamoudi Saudi Arabia	11	205 1.2×	151 0.9×	29 0.6×	17 1.1×	2 0.2×	21	244

Countries citing papers authored by Milotka Fabri

Since Specialization

Citations

This map shows the geographic impact of Milotka Fabri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milotka Fabri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milotka Fabri more than expected).

Fields of papers citing papers by Milotka Fabri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Milotka Fabri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milotka Fabri. The network helps show where Milotka Fabri may publish in the future.

Co-authorship network of co-authors of Milotka Fabri

This figure shows the co-authorship network connecting the top 25 collaborators of Milotka Fabri. A scholar is included among the top collaborators of Milotka Fabri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milotka Fabri. Milotka Fabri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fabri, Milotka, et al.. (2021). IMPLEMENTATION OF MICROELIMINATION STRATEGY IN ERADICATION OF CHRONIC HEPATITIS C INFECTION IN PATIENTS WITH HEMOPHILIA IN THE NORTHERN REGION OF SERBIA. Mediterranean Journal of Hematology and Infectious Diseases. 13(1). e2021058–e2021058. 2 indexed citations

Fabri, Milotka, et al.. (2019). Validity of hepatitis B and hepatitis C case definitions. Journal of Infection and Public Health. 12(4). 516–521. 8 indexed citations

Pellicano, Rinaldo, Milotka Fabri, Francesco Luzza, et al.. (2018). Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Medica. 60(4). 185–191. 26 indexed citations

Lendak, Dajana, et al.. (2017). Novel infectious diseases in europe. Medicinski pregled. 70(11-12). 385–390. 1 indexed citations

Horváth, Gábor, George Papatheodoridis, Milotka Fabri, et al.. (2016). Rg-101 in Combination With 4 Weeks of Oral Direct Acting Antiviral Therapy Achieves High Virologic Response Rates in Treatment Naïve Genotype 1 and 4 Chronic Hepatitis C Patients: Interim Results from a Randomised, Multicenter, Phase 2 Study. Journal of Hepatology. 64(2). S159–S159. 2 indexed citations

Fabri, Milotka, et al.. (2015). Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia. Srpski arhiv za celokupno lekarstvo. 143(1-2). 35–41. 2 indexed citations

Fung, Scott, Peter Kwan, Milotka Fabri, et al.. (2013). Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B. Gastroenterology. 146(4). 980–988.e1. 114 indexed citations

Fabri, Milotka, et al.. (2013). Treatment of acute hepatitis C in breast cancer patient: a case report. Journal of Chemotherapy. 26(3). 180–183. 3 indexed citations

Fabri, Milotka, et al.. (2013). Hepatitis B reactivation after therapy for non-Hodgkin lymphoma: A case report with review of literature. Archive of oncology. 21(3-4). 151–154.

10.

Kwan, Peter, Andrzej Horban, Petr Husa, et al.. (2013). 744 TENOFOVIR DF (TDF) IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH PRE-EXISTING MILD RENAL IMPAIRMENT. Journal of Hepatology. 58. S301–S302. 7 indexed citations

11.

Fabri, Milotka, et al.. (2013). Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with Pegylated interferon alfa-2a and ribavirin. Srpski arhiv za celokupno lekarstvo. 141(5-6). 320–324. 2 indexed citations

12.

Fabri, Milotka, Franklin C. Wong, Selım Gürel, et al.. (2011). 368 REDUCED BONE MINERAL DENSITY DERIVED FROM DUAL X-RAY ABSORPTIOMETRY ASSESSMENTS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB). Journal of Hepatology. 54. S148–S148. 2 indexed citations

13.

Fabri, Milotka, et al.. (2010). Clinical manifestations of leptospirosis. International Journal of Infectious Diseases. 14. e164–e164. 1 indexed citations

14.

Fabri, Milotka, et al.. (2010). Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users. Srpski arhiv za celokupno lekarstvo. 138(1-2). 43–49. 3 indexed citations

15.

Svirčev, Zorica, et al.. (2009). Leptospirosis distribution related to freshwater habitats in the Vojvodina region (Republic of Serbia). Science in China Series C Life Sciences. 52(10). 965–971. 16 indexed citations

16.

Fabri, Milotka, et al.. (2009). Exercise induced rhabdomyolysis. Vojnosanitetski pregled. 66(9). 754–757. 2 indexed citations

17.

Fabri, Milotka, et al.. (2009). Immunomodulatory actions of antibiotics. Medicinski pregled. 62(7-8). 327–330. 5 indexed citations

18.

Schneider, Joel, Waldemar Halota, Dragan Delić, et al.. (2006). O.101 A novel primboost therapeutic vaccine induces sustained seroconversion at 52 weeks in patients with HBeAg+ chronic hepatitis B: A phase IIa clinical trial. Journal of Clinical Virology. 36. S30–S30. 4 indexed citations

19.

Fabri, Milotka, et al.. (2003). Treatment of chronic hepatitis C with pegylated-interferon. Medicinski pregled. 56(9-10). 427–430. 2 indexed citations

20.

Simić, Marija, Rade Vuković, & Milotka Fabri. (1990). [Damage in the hemato-enteral barrier in experimental liver transplantation].. PubMed. 37 Suppl 1. 75–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact